CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Ammoniated mercury +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02028208
NCT02028208Phase 2Completed
CompareCT.gov

Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study

Allerderm·interventional·Posted Jan 7, 2014·Updated Aug 24, 2020

In Brief

A Phase 2 clinical trial evaluating Ammoniated mercury, Aluminum chloride and aluminum lactate, and 1 other intervention for Contact Dermatitis. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the diagnostic performance and safety of ascending doses of mercury, aluminum and palladium metal allergens proposed for inclusion in a metal allergen panel. Optimal dose will be selected based on the lowest dose of each allergen eliciting a positive response in 70-90% of subjects tested.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContact Dermatitis
CountriesSweden
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 7, 2014
Enrollment StartNov 4, 2013
Primary CompletionMay 24, 2016
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 12.5 years ago

Interventions

Ammoniated mercuryother

Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.

Aluminum chloride and aluminum lactateother

Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.

Sodium tetrachloropalladateother

Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.